Is vitamin B6 (pyridoxine) an effective treatment for tardive dyskinesia?

Vitamin B6 for Tardive Dyskinesia

Vitamin B6 is NOT a first-line treatment for tardive dyskinesia; VMAT2 inhibitors should be used for moderate to severe or disabling TD, as recommended by the American Psychiatric Association. 1

Primary Treatment Recommendation

The 2020 APA guideline explicitly states that patients with moderate to severe or disabling tardive dyskinesia should be treated with a reversible VMAT2 inhibitor (1B recommendation) 1. This is the only pharmacological intervention that receives a formal recommendation in current major guidelines for TD treatment.

Evidence for Vitamin B6

While vitamin B6 shows some promise in research studies, the evidence has significant limitations:

Supporting Evidence

• Two small trials from the same research group (2001 and 2007) demonstrated significant improvement in TD symptoms with vitamin B6 (doses 400-1200 mg/day) compared to placebo 2, 3
• A 2020 meta-analysis found vitamin B6 associated with significant TD symptom reduction (SMD = 1.41), but this was based solely on those two trials from the same investigators 4
• A 2015 Cochrane review concluded vitamin B6 "may have some benefits" but rated the evidence quality as low due to small sample sizes, short follow-up periods, and inadequate reporting 5

Critical Limitations

• Only 2 trials (both from the same research group in Israel) support B6 efficacy
• Total of only 65 patients studied across both trials
• No independent replication of findings by other research groups
• Evidence quality rated as low by Cochrane 5
• Not mentioned in current treatment guidelines as a recommended option 1, 6

Clinical Algorithm

For patients with moderate to severe or disabling TD:

1. First-line: Initiate VMAT2 inhibitor (valbenazine or deutetrabenazine) 1
2. Concurrent: Consider reducing antipsychotic dose or switching to clozapine if clinically appropriate 1, 7
3. Alternative options (if VMAT2 inhibitors unavailable or not tolerated): Amantadine has moderate evidence 4
4. Vitamin B6: May be considered as adjunctive therapy given low risk profile, but should not replace evidence-based first-line treatment

For mild TD:

• Reduce antipsychotic dose to minimum effective level
• Consider switching to second-generation antipsychotic or clozapine
• Monitor closely with AIMS scale

Important Caveats

• VMAT2 inhibitors have the strongest evidence from multiple large, well-designed trials 4, 7
• Vitamin E showed apparent benefit in meta-analysis but had significant publication bias, with shorter duration and lower doses paradoxically showing greater benefit—suggesting the evidence may be overstated 4
• Prevention is critical since TD can be irreversible: use antipsychotics only when necessary, at lowest effective doses, with regular monitoring 8, 7
• The lack of vitamin B6 in any current treatment guidelines 1, 6, 9 despite decades since the original studies suggests the medical community has not found the evidence compelling enough to adopt

Bottom Line

While vitamin B6 may provide some benefit based on limited evidence, it should not be used as monotherapy for moderate to severe TD when VMAT2 inhibitors are available and have strong guideline support 1. If considering vitamin B6, use it only as adjunctive therapy alongside evidence-based treatments, recognizing the evidence base consists of only two small trials from a single research group.